Lyfe Rx offered compounded semaglutide and tirzepatide online with false 'clinically proven weight loss' claims, FDA says.
What happened
FDA reviewed the company's website at https://thelyferx.com in August 2025. The site offered compounded semaglutide and tirzepatide and claimed 'Clinically Proven Weight Loss' for each. FDA says those claims are false or misleading because compounded drugs are not FDA-approved and the claims imply they are the same as approved products.
What FDA found
FDA says the website claim 'Clinically Proven Weight Loss' for compounded semaglutide is false or misleading because compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA says the same 'Clinically Proven Weight Loss' claim for compounded tirzepatide is false or misleading for the same reason.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]The company introduced or delivered misbranded semaglutide and tirzepatide products into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]Receiving or delivering misbranded drugs in interstate commerce is also a prohibited act.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, FDA asks Lyfe Rx to send a written response to CDER's Office of Compounding Quality and Compliance describing specific steps taken to address the violations, prevent recurrence, and include related documents. If the company believes its products are not in violation, it must include its reasoning and supporting information.
Who should pay attention
- telehealth companies selling compounded semaglutide or tirzepatide
- compounding pharmacies and their marketing partners
- clinics and brands advertising compounded weight-loss drugs
This is a summary. Read the original letter on fda.gov.